Search Results - "Blakely, Collin"

A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations by Blakely, Collin M

“…The clinical utility of performing tumor genetic testing to assess for alterations beyond the known targetable oncogenes in lung adenocarcinoma is unclear…”
Get full text

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers by Nichols, Robert J., Haderk, Franziska, Stahlhut, Carlos, Schulze, Christopher J., Hemmati, Golzar, Wildes, David, Tzitzilonis, Christos, Mordec, Kasia, Marquez, Abby, Romero, Jason, Hsieh, Tientien, Zaman, Aubhishek, Olivas, Victor, McCoach, Caroline, Blakely, Collin M., Wang, Zhengping, Kiss, Gert, Koltun, Elena S., Gill, Adrian L., Singh, Mallika, Goldsmith, Mark A., Smith, Jacqueline A. M., Bivona, Trever G.

“…Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAF…”
Get full text

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer by Shah, Khyati N., Bhatt, Roma, Rotow, Julia, Rohrberg, Julia, Olivas, Victor, Wang, Victoria E., Hemmati, Golzar, Martins, Maria M., Maynard, Ashley, Kuhn, Jonathan, Galeas, Jacqueline, Donnella, Hayley J., Kaushik, Swati, Ku, Angel, Dumont, Sophie, Krings, Gregor, Haringsma, Henry J., Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., McCormick, Frank, Goga, Andrei, Blakely, Collin M., Bivona, Trever G., Bandyopadhyay, Sourav

“…Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired…”
Get full text

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials by Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D

“…Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene…”
Get full text

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer by Halliday, Patrick R., Blakely, Collin M., Bivona, Trever G.

“…Purpose of Review Lung cancer remains the leading cause of cancer-related mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer…”
Get full text

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing by Maynard, Ashley, McCoach, Caroline E., Rotow, Julia K., Harris, Lincoln, Haderk, Franziska, Kerr, D. Lucas, Yu, Elizabeth A., Schenk, Erin L., Tan, Weilun, Zee, Alexander, Tan, Michelle, Gui, Philippe, Lea, Tasha, Wu, Wei, Urisman, Anatoly, Jones, Kirk, Sit, Rene, Kolli, Pallav K., Seeley, Eric, Gesthalter, Yaron, Le, Daniel D., Yamauchi, Kevin A., Naeger, David M., Bandyopadhyay, Sourav, Shah, Khyati, Cech, Lauren, Thomas, Nicholas J., Gupta, Anshal, Gonzalez, Mayra, Do, Hien, Tan, Lisa, Bacaltos, Bianca, Gomez-Sjoberg, Rafael, Gubens, Matthew, Jahan, Thierry, Kratz, Johannes R., Jablons, David, Neff, Norma, Doebele, Robert C., Weissman, Jonathan, Blakely, Collin M., Darmanis, Spyros, Bivona, Trever G.

“…Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables adaptability, limits therapeutic success, and remains incompletely…”
Get full text

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer by Blakely, Collin M., Pazarentzos, Evangelos, Olivas, Victor, Asthana, Saurabh, Yan, Jenny Jiacheng, Tan, Irena, Hrustanovic, Gorjan, Chan, Elton, Lin, Luping, Neel, Dana S., Newton, William, Bobb, Kathryn L., Fouts, Timothy R., Meshulam, Jeffrey, Gubens, Matthew A., Jablons, David M., Johnson, Jeffrey R., Bandyopadhyay, Sourav, Krogan, Nevan J., Bivona, Trever G.

“…Although oncogene-targeted therapy often elicits profound initial tumor responses in patients, responses are generally incomplete because some tumor cells…”
Get full text

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer by McCoach, Caroline E, Blakely, Collin M, Banks, Kimberly C, Levy, Benjamin, Chue, Ben M, Raymond, Victoria M, Le, Anh T, Lee, Christine E, Diaz, Joseph, Waqar, Saiama N, Purcell, William T, Aisner, Dara L, Davies, Kurtis D, Lanman, Richard B, Shaw, Alice T, Doebele, Robert C

“…Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase ( gene fusions benefit from treatment with ALK…”
Get full text

Inactivation of Capicua drives cancer metastasis by Okimoto, Ross A, Breitenbuecher, Frank, Olivas, Victor R, Wu, Wei, Gini, Beatrice, Hofree, Matan, Asthana, Saurabh, Hrustanovic, Gorjan, Flanagan, Jennifer, Tulpule, Asmin, Blakely, Collin M, Haringsma, Henry J, Simmons, Andrew D, Gowen, Kyle, Suh, James, Miller, Vincent A, Ali, Siraj, Schuler, Martin, Bivona, Trever G

“…Trever Bivona and colleagues use an in vivo lung cancer metastasis model to show that the transcriptional repressor Capicua (CIC) suppresses invasion and…”
Get full text

Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies by Blakely, Collin M, McCoach, Caroline E

“…Overall survival and disease-free survival have been the gold standard primary endpoints for neoadjuvant clinical trials. Major pathologic response is a…”
Get full text

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer by Gini, Beatrice, Thomas, Nicholas, Blakely, Collin M.

“…Comprehensive characterization of the genomic landscape of epidermal growth factor receptor ( EGFR )-mutated lung cancers have identified patterns of secondary…”
Get full text

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins by Neel, Dana S, Allegakoen, David V, Olivas, Victor, Mayekar, Manasi K, Hemmati, Golzar, Chatterjee, Nilanjana, Blakely, Collin M, McCoach, Caroline E, Rotow, Julia K, Le, Anh, Karachaliou, Niki, Rosell, Rafael, Riess, Jonathan W, Nichols, Robert, Doebele, Robert C, Bivona, Trever G

“…Chromosomal rearrangements involving receptor tyrosine kinases (RTK) are a clinically relevant oncogenic mechanism in human cancers. These chimeric…”
Get full text

Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review by Blakely, Collin M., Weder, Walter, Bubendorf, Lukas, He, Jianxing, Majem, Margarita, Shyr, Yu, Chaft, Jamie E.

“…•Treatments are limited in early-stage resectable NSCLC with targetable alterations.•In this setting, long overall survival follow-up can delay regulatory…”
Get full text

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer by Hrustanovic, Gorjan, Olivas, Victor, Pazarentzos, Evangelos, Tulpule, Asmin, Asthana, Saurabh, Blakely, Collin M, Okimoto, Ross A, Lin, Luping, Neel, Dana S, Sabnis, Amit, Flanagan, Jennifer, Chan, Elton, Varella-Garcia, Marileila, Aisner, Dara L, Vaishnavi, Aria, Ou, Sai-Hong I, Collisson, Eric A, Ichihara, Eiki, Mack, Philip C, Lovly, Christine M, Karachaliou, Niki, Rosell, Rafael, Riess, Jonathan W, Doebele, Robert C, Bivona, Trever G

“…Unraveling the signaling dependencies of EMLK4-ALK fusion–driven lung cancer reveals upfront combination therapy strategies. One strategy for combating…”
Get full text

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer by Nanjo, Shigeki, Wu, Wei, Karachaliou, Niki, Blakely, Collin M, Suzuki, Junji, Chou, Yu-Ting, Ali, Siraj M, Kerr, D Lucas, Olivas, Victor R, Shue, Jonathan, Rotow, Julia, Mayekar, Manasi K, Haderk, Franziska, Chatterjee, Nilanjana, Urisman, Anatoly, Yeo, Jia Chi, Skanderup, Anders J, Tan, Aaron C, Tam, Wai Leong, Arrieta, Oscar, Hosomichi, Kazuyoshi, Nishiyama, Akihiro, Yano, Seiji, Kirichok, Yuriy, Tan, Daniel Sw, Rosell, Rafael, Okimoto, Ross A, Bivona, Trever G

“…Molecularly targeted cancer therapy has improved outcomes for cancer patients with targetable oncoproteins, such as mutant epidermal growth factor receptor…”
Get full text

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer by Noronha, Ashish, Belugali Nataraj, Nishanth, Lee, Joo Sang, Zhitomirsky, Benny, Oren, Yaara, Oster, Sara, Lindzen, Moshit, Mukherjee, Saptaparna, Will, Rainer, Ghosh, Soma, Simoni-Nieves, Arturo, Verma, Aakanksha, Chatterjee, Rishita, Borgoni, Simone, Robinson, Welles, Sinha, Sanju, Brandis, Alexander, Kerr, D Lucas, Wu, Wei, Sekar, Arunachalam, Giri, Suvendu, Chung, Youngmin, Drago-Garcia, Diana, Danysh, Brian P, Lauriola, Mattia, Fiorentino, Michelangelo, Ardizzoni, Andrea, Oren, Moshe, Blakely, Collin M, Ezike, Jideofor, Wiemann, Stefan, Parida, Laxmi, Bivona, Trever G, Aqeilan, Rami I, Brugge, Joan S, Regev, Aviv, Getz, Gad, Ruppin, Eytan, Yarden, Yosef

“…Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes…”
Get more information

Targeting MEK in non-small cell lung cancer by Lara, Matthew S., Blakely, Collin M., Riess, Jonathan W.

“…The mitogen-activated protein kinase (MAPK or MEK) pathway modulates tumor cell survival and proliferation in non-small cell lung cancer (NSCLC). Unlike RAS or…”
Get full text

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC by Blakely, Collin M., Riess, Jonathan W.

“…Introduction: Lung cancer is the leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung…”
Get full text

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report by Kim, Dong-Wan, Kim, Sang-We, Camidge, D Ross, Shu, Catherine A, Marrone, Kristen A, Le, Xiuning, Blakely, Collin M, Park, Keunchil, Chang, Gee-Chen, Patel, Sandip Pravin, Kar, Gozde, Cooper, Zachary A, Samadani, Ramin, Pluta, Michael, Kumar, Rakesh, Ramalingam, Suresh

“…CD73 is overexpressed in EGFR-mutated NSCLC and may promote immune evasion, suggesting potential for combining CD73 blockers with EGFR tyrosine kinase…”
Get more information

Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment by Douglas, Michael P, Ragavan, Meera V, Chen, Cheng, Kumar, Anika, Gray, Stacy W, Blakely, Collin M, Phillips, Kathryn A

“…Circulating tumor DNA (ctDNA) is used to select initial targeted therapy, identify mechanisms of therapeutic resistance, and measure minimal residual disease…”
Get more information